$APTOF

Vincent Mark D. sold (to issuer) $24 of APTOF

Vincent Mark D. sold (to issuer) 14 shares of Aptose Biosciences Inc. (APTOF) at $1.72 on 2026-06-13.

Original reporting
SEC EDGAR · Vincent Mark D.
Published Jul 1, 2026, 9:03 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 1, 2026, 9:10 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$APTOF
Neutral
high confidence
Mentioned
$APTOF
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$APTOFNeutralLow
01

Why it matters

The filing provides a fresh datapoint on insider selling activity but does not include any new company-specific fundamentals (no guidance, trial results, deals, or regulatory actions).

02

Market read

Traders may note insider selling, but the transaction size ($24.08) and lack of fundamental catalysts make it low signal.

03

What to watch

No 10b5-1 plan is cited and the insider ends with 0 shares, but the disclosure lacks context on motivations or broader insider activity.

Relevance 3/10Novelty 2/10Timing: filed after-hours on 2026-07-01 (SEC EDGAR Form 4)

Background

The article is an SEC Form 4 insider transaction disclosure for Aptose Biosciences Inc.

Company-level read

Ticker impact

$APTOFNeutralHigh confidence
Context

Aptose Biosciences insider Vincent Mark D. sold 14 shares to the issuer at $1.72/share, leaving 0 shares after the transaction.

Expected impact

Minimal near-term impact; any effect is likely short-lived and sentiment-only.

Evidence & confidence

Form 4 shows a small transaction ($24.08) and indicates holdings drop to zero; no new operational, regulatory, or financial datapoints are disclosed.

Market effects

No sector read-through; this is a single, small insider transaction.

None indicated.

None indicated.

Counterpoint

The “sale to issuer” code D can reflect mechanical buyback participation rather than bearish signaling, so the market may ignore it.

Key entities

  • Aptose Biosciences Inc.

    Subject of the Form 4 insider transaction disclosure (APTOF).

  • Vincent Mark D.

    Insider who sold 14 shares to the issuer at $1.72/share on 2026-06-13.

Related articles

$APTOFMed

Aptose Biosciences Inc. (APTOF): Completion of Acquisition or Disposition of Assets

Aptose Biosciences Inc. (APTOF) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. 8-K false 0000882361 0000882361 2026-06-30 2026-06-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30,